Navigation Links
Regenicin to Form Scientific Advisory Board
Date:10/19/2010

NEW YORK Oct. 19 /PRNewswire-FirstCall/ -- Regenicin, Inc. (OTC Bulletin Board: WDST), a development stage biotechnology company, announced today that they have begun identifying candidates for the formation of a Scientific Advisory Board.  The board will include thought leaders, scientists and physicians in the fields of regenerative medicine, cellular biology, dermatology and burn and wound treatment. Appointees will play a key role in advising Regenicin on the company's current and future research and development programs as well as in corporate strategies for global expansion.

"We look forward to assembling a team that can provide objective feedback and guidance on Regenicin's efforts to develop and deliver breakthrough treatments for chronic burns and wounds," says Randall McCoy, CEO of Regenicin. "Currently we have identified our key candidates and will announce them individually upon full approval by our board of directors." Regenicin expects to have the full Scientific Advisory Board is in place within the next ninety days.

About Regenicin, Inc.

Regenicin, Inc. is a development stage company focusing on next-generation tissue-engineered skin substitutes to restore the qualities of healthy human skin. Regenicin is a publicly traded company, with headquarters in Little Falls, NJ. Additional information can be found in the company's filings with the Securities and Exchange Commission located at www.sec.gov.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Regenicin(TM), Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Regenicin Names Former U.S. Marine Corp Operations Officer, Christopher Hadsall, Chief Operating Officer
2. Former Fujifilm Medical Systems USA Executive John J. Weber Agrees to Join Regenicin™ as a Member of Its Board of Directors and Interim CFO
3. Regenicin Completes Acquisition of Worldwide Exclusive Know-How Technology License from Lonza Walkersville
4. Generex Scientific Advisor Weighs in on Reverse Stock Split Proposal
5. Glencoe Software and The Journal of Cell Biology Pioneer Online Publishing of Scientific Image Data: New Version of JCB DataViewer Released
6. Orexigen® Therapeutics Announces Upcoming Data Presentations at the 28th Annual Scientific Meeting of The Obesity Society
7. Pepscan Therapeutics Announces Establishment of Scientific Advisory Board
8. Elsevier Survey Reveals Researchers Ready to Push Scientific Search and Discovery to the Next Level
9. Metamark Genetics, Inc. Announces New Chief Scientific Officer
10. Fibrocell Science, Inc. Names Biotechnology and Genetic Research Expert Stefan Gruenwald, M.D., Ph.D., to Scientific Advisory Board
11. American Humane Association Announces Joy Mench, Ph.D., Joins the Scientific Advisory Committee of the American Humane Certified® Farm Animal Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , Feb. 11, 2016  Dovetail Genomics™ LLC today ... beta program for a planned metagenomic genome assembly service. ... company,s metagenomic genome assembly method in a talk on ... Biology & Technology conference in Orlando, Fla. ... highly complex datasets is difficult. Using its proprietary ...
(Date:2/11/2016)... ... , ... Global Stem Cells Group, has announced ... new facility will provide advanced protocols and state-of-the-art techniques in cellular medicine, focusing ... The new GSCG clinic is headed by four prominent Ecuadorian physicians, including Pablo ...
(Date:2/10/2016)... , Feb.10, 2016 ASAE is introducing a ... Management Companies (AMC) the option of joining or renewing ... fee determined by staff size, every employee in any ... ASAE and reap all available member benefits.   ... new organizational membership options will allow organizations of any ...
(Date:2/10/2016)... ... 2016 , ... Benchmark Research, a fully-integrated network of ... principal investigators (PI) to the roles of Chief Medical Officer, Clinical Research and ... Chu, a Benchmark Research PI in the Austin office, will assume the role ...
Breaking Biology Technology:
(Date:1/21/2016)... January 21, 2016 ... new market research report "Emotion Detection and Recognition Market by ... Tools (Facial Expression, Voice Recognition and Others), Services, ... forecast to 2020", published by MarketsandMarkets, the global ... reach USD 22.65 Billion by 2020, at a ...
(Date:1/18/2016)... Jan. 18, 2016  Extenua Inc., a pioneering ... the use and access of ubiquitous on-premise and ... with American Cyber.  ... leading transformational C4ISR and Cyber initiatives in support ... latest proven technology solutions," said Steve Visconti ...
(Date:1/11/2016)... Calif. , Jan. 11, 2016 Synaptics ... human interface solutions, today announced that its ClearPad ® ... integration (TDDI) products won two separate categories in the ... Mobile Innovator and Best Technology Breakthrough. The Synaptics ® ... cost, a simplified supply chain, thinner devices, brighter displays ...
Breaking Biology News(10 mins):